Heart valve repair patients: which blood thinner is safest?

NCT ID NCT07007143

Recruiting now Disease control Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best blood-thinning medicine after a minimally invasive heart valve repair for mitral regurgitation, a common heart condition. About 1,032 participants will be randomly assigned to take either aspirin alone or aspirin plus clopidogrel. The goal is to see which approach causes fewer bleeding problems over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin and clopidogrel (blood thinners)
What this could lead to: If successful, this could establish a safer standard blood-thinning regimen after mitral valve repair, reducing bleeding complications while maintaining effectiveness.
What could go wrong: This is a Phase 4 trial, so the drugs are already approved, but the optimal combination for this specific procedure is unknown. Results may not apply to all patients, and bleeding risks remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MITRAL REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Embolism and Thrombosis Hemorrhage mitral valve insufficiency myocardial infarction stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MITRAL REGURGITATION

Contacts and locations

Locations

Chinese Academy of Medical Sciences, Fuwai Hospital
RECRUITING

Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.